Tenax Therapeutics, Inc. (TENX): R&D Expense
$32.67M
Year ended 2025-12-31
$45.26M
Trailing 12 months to 2026-06-30
+82.5%
3-year compound annual growth
+48.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $32.67M | +157.1% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $12.71M | +293.6% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $3.23M | -40.0% | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $5.38M | -78.6% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $25.15M | +451.4% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $4.56M | +31.4% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $3.47M | +180.1% | 2021-04-16, From 2019-01-01 |
| 2018-12-31 | $1.24M | -64.9% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $3.53M | -73.2% | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $13.14M | n/a | 2018-04-02, From 2016-01-01 |
| No annual figure between 2015-04-30 and 2016-12-31. | |||
| 2015-04-30 | $6.66M | +122.3% | 2017-03-16, From 2014-05-01 |
| 2014-04-30 | $3.00M | +22.0% | 2017-03-16, From 2013-05-01 |
| 2013-04-30 | $2.46M | -0.3% | 2014-07-29, From 2012-05-01 |
| 2012-04-30 | $2.46M | -8.2% | 2013-06-26, From 2011-05-01 |
| 2011-04-30 | $2.68M | n/a | 2012-07-25, From 2010-05-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $32.67M | +157.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare TENX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗